• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Sumavel DosePro (sumatriptan) injection for subcutaneous use

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – June 2011 

Summary View  

 

 

CONTRAINDICATIONS

Do not use within 24 hours of treatment with Ergotamine-Containing or Ergot-Type Medications or Other 5-HT1 Agonists (e.g. triptans)
  • ...(with the exception of a single dose of another sumatriptan product, provided the doses are separated by at least 1 hour)